126 related articles for article (PubMed ID: 8561838)
1. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
Puryear LJ; Kunik ME; Workman R
J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):234-7. PubMed ID: 8561838
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
Martinez JM; Russell JM; Hirschfeld RM
Depress Anxiety; 1998; 7(2):83-6. PubMed ID: 9614597
[TBL] [Abstract][Full Text] [Related]
3. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
Wassef AA; Winkler DE; Roache AL; Abobo VB; Lopez LM; Averill JP; Mian AI; Overall JE
Am J Psychiatry; 2005 Feb; 162(2):330-9. PubMed ID: 15677599
[TBL] [Abstract][Full Text] [Related]
4. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Scheffer RE; Kowatch RA; Carmody T; Rush AJ
Am J Psychiatry; 2005 Jan; 162(1):58-64. PubMed ID: 15625202
[TBL] [Abstract][Full Text] [Related]
5. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study.
Zarate CA; Tohen M; Narendran R; Tomassini EC; McDonald J; Sederer M; Madrid AR
J Clin Psychiatry; 1999 Apr; 60(4):232-6. PubMed ID: 10221283
[TBL] [Abstract][Full Text] [Related]
6. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
Sherr JD; Kelly DL
Psychiatr Serv; 1998 Oct; 49(10):1355-7. PubMed ID: 9779912
[TBL] [Abstract][Full Text] [Related]
7. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
Horne RL; Cunanan C
J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
[TBL] [Abstract][Full Text] [Related]
9. Divalproex sodium in the treatment of aggressive behavior.
Wilcox J
Ann Clin Psychiatry; 1994 Mar; 6(1):17-20. PubMed ID: 7951640
[TBL] [Abstract][Full Text] [Related]
10. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
[TBL] [Abstract][Full Text] [Related]
11. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
12. Divalproex extended-release in acute bipolar II depression.
Wang PW; Nowakowska C; Chandler RA; Hill SJ; Nam JY; Culver JL; Keller KL; Ketter TA
J Affect Disord; 2010 Jul; 124(1-2):170-3. PubMed ID: 19923006
[TBL] [Abstract][Full Text] [Related]
13. Comorbid anxiety disorders and divalproex sodium use among partial hospital patients with psychotic disorders.
Townsend MH; Wilson MS
Compr Psychiatry; 2005; 46(5):368-70. PubMed ID: 16122537
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder.
Suppes T; Kelly DI; Hynan LS; Snow DE; Sureddi S; Foster B; Curley E
Aust N Z J Psychiatry; 2007 May; 41(5):397-402. PubMed ID: 17464731
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Tohen M; Ketter TA; Zarate CA; Suppes T; Frye M; Altshuler L; Zajecka J; Schuh LM; Risser RC; Brown E; Baker RW
Am J Psychiatry; 2003 Jul; 160(7):1263-71. PubMed ID: 12832240
[TBL] [Abstract][Full Text] [Related]
16. Extended-release divalproex sodium for mood stabilization.
Stoner SC; Dubisar BM; Lea JW; Marken PA; Ramlatchman LV; Reynolds JB
Pharmacotherapy; 2004 Sep; 24(9):1147-53. PubMed ID: 15460175
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder.
MacMillan CM; Withney JE; Korndörfer SR; Tilley CA; Mrakotsky C; Gonzalez-Heydrich JM
J Psychiatr Pract; 2008 May; 14(3):160-9. PubMed ID: 18520785
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
Hirschfeld RM; Bowden CL; Vigna NV; Wozniak P; Collins M
J Clin Psychiatry; 2010 Apr; 71(4):426-32. PubMed ID: 20361904
[TBL] [Abstract][Full Text] [Related]
19. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury.
Kim E; Humaran TJ
J Neuropsychiatry Clin Neurosci; 2002; 14(2):202-5. PubMed ID: 11983796
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances.
Kunik ME; Puryear L; Orengo CA; Molinari V; Workman RH
Int J Geriatr Psychiatry; 1998 Jan; 13(1):29-34. PubMed ID: 9489578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
